Research programme: antibody therapeutics - Sevion TherapeuticsAlternative Names: FB 001; FB 002; FB 003; FB 004; G protein-coupled receptor modulators - Sevion Therapeutics; Ion channel antagonists - Sevion Therapeutics; SVN-001; SVN-002
Latest Information Update: 01 Dec 2014
At a glance
- Originator Fabrus
- Developer Sevion Therapeutics
- Class Antibodies
- Mechanism of Action Angiogenesis modulating agents; G protein-coupled receptor modulators; Immunomodulators; Ion channel antagonists; Kv1.3 potassium channel inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer; Inflammation
- Research Pain